One-year results from a randomised study comparing fibred platinum coils to vascular plugs for the embolization of pelvic varices in order to treat pelvic congestion syndrome have shown that plugs are as good as coils with regard to safety and efficacy. In addition, plugs also significantly reduce procedure and fluoroscopy time, and radiation dose, the study finds.
The audience in the CIRSE 2014 “Controversies in superficial femoral artery treatment” session failed to endorse two motions pertaining to drug-elution in this anatomical segment in the annual meeting (12–17 September, Glasgow, UK). The first motion was “drug-eluting stents will show better five-year patency rates than percutaneous transluminal angioplasty” and the other was “Drug-eluting balloons in all superficial femoral artery lesions”. While the majority vote went against both motions, leaving the proponents of drug-eluting devices disappointed, experts have questioned whether a motion that was more specific with respect to lesion type and length might have elicited a different voting result.
William T Kuo presented the initial results of the PERFECT registry at CIRSE 2014 (the annual meeting of the Cardiovascular and Interventional Radiological Society of Europe, 12–17 September, Glasgow, UK). He explained that systemic thrombolysis for acute pulmonary embolism carries up to a 20% risk of major bleeding, including a 2–5% risk of haemorrhagic stroke.
A special session at the CIRSE 2014 conference in Glasgow, UK, took a close look at the field of renal denervation as it stands today and concluded that there is still plenty of life and promise in the field. This is not the end of renal denervation but the beginning of proper evaluation, experts said.
Celsion Corporation has announced that the first patient has been enrolled in its pivotal phase III OPTIMA study of ThermoDox in combination with optimised radiofrequency ablation in patients with hepatocellular carcinoma. The first patient was treated at Kyungpook National University Hospital in South Korea.
A study group at the Comprehensive Cancer Centre of Medical University of Vienna and AKH Vienna under the guidance of Maria Sibilia from the Institute for Cancer Research has discovered that tumorigenisis of epidermal growth factor receptor (EGFR) does not, as previously assumed, depend on its presence within the tumour cell, but rather from its activity in the cells adjacent to the tumour.
Despite the rapid growth of imaging and treatment options in interventional oncology, one area that has been poorly understood and overlooked by the interventional community is the role of the tumour microenvironment and its impact on the delivery of therapeutic agents.
Vascular Solutions has announced the US market launch of its Gel-Bead embolization spheres for the treatment of hypervascular tumours
DFINE has announced the publication of a multicentre study in the July/August issue of Pain Physician Journal, the official peer-reviewed publication of the American Society of Interventional Pain Physicians (ASIPP). The study followed patients at five leading academic centres and found a significant decrease (p <0.01) in pain scores after targeted radiofrequency ablation (t-RFA) with the Star tumour ablation system
Overcoming a significant roadblock to predictable ablation of soft tissue, Covidien has unveiled an advanced ablation system that offers physicians predictable results regardless of the target location or tissue type. The Emprint ablation system with Thermosphere technology is designed to precisely heat and destroy diseased soft tissue (including liver, lung and kidney), and non-resectable liver tumours.
The evidence supporting the use of transarterial chemoembolization (TACE) and Yttrium-90 transarterial radioembolization (TARE) to treat primary and secondary liver malignancies for palliation, survival benefit, bridging or downstaging to liver transplant or hepatic resection is expanding, both with respect to volume and quality. As a result, the number of these procedures being performed is on the rise. However, unintended non target delivery of TACE or TARE agents into any of the various hepaticoentric arteries that course from an intrahepatic artery to implant into an extra hepatic organ such as the stomach or small intestine can result in serious complications, especially gastrointestinal ulcerations, particularly with Y-90 microspheres. In the 1990s, the reported rates of such ulcerations was in the range of 15%. Subsequently, with standard lobar or sublobar dose delivery, rigorous coil embolization of all identified hepaticoentric arteries, and liberal use of core beam CT, the reported rate of gastrointestinal ulceration from TARE generally reduced to the range of 2–5%. Thorough coil embolic protection is both technically challenging and time consuming, and occasionally cannot be accomplished. An unintended consequence of coil embolization of the gastroduodenal artery is the subsequent angiographic appearance of “new” hepaticoentric arteries such as the supraduodenal artery that occur in 35% of patients. These are difficult, and at times impossible to catheterise and to place microcoils in.
Boston Scientific Corporation closed on its previously announced agreement to purchase the Interventional business of Bayer AG. The acquisition enhances the ability of Boston Scientific to offer physicians and healthcare systems a more complete portfolio of solutions to treat challenging vascular conditions.
CeloNova has announced US FDA 510(k) clearance expanding the indication for their Oncozene and Embozene microsphere products to now include the embolization of hepatocellular carcinoma.
Kona Medical has announced the initiation of the WAVE IV, randomised, sham-controlled, double-blinded, clinical trial of its Surround Sound Hypertension Therapy System. The trial will treat 132 patients at sites in Europe, New Zealand, Australia, and South America.
Covidien has announced that it has acquired Sapheon, a privately-held developer of venous disease treatments. Financial terms of the transaction were not disclosed
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos